For example, one large meta-analysis of 13 studies with over 3000 metastatic NSCLC patients reported a significantly worse progression-free survival (PFS) with a hazard ratio (HR) of 1.3; p = <0.05 for KRAS mutant patients compared to those with KRAS wild-type (WT) after receiving first- or second-line platinum-based chemotherapy [19]. Here, KRAS is linked to non-small cell lung carcinoma.